These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 30657024

  • 1. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.
    Marková J.
    Neurodegener Dis Manag; 2019 Apr; 9(2s):9-13. PubMed ID: 30657024
    [Abstract] [Full Text] [Related]

  • 2. Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.
    Ziemssen T.
    Neurodegener Dis Manag; 2019 Apr; 9(2s):1-2. PubMed ID: 30657019
    [Abstract] [Full Text] [Related]

  • 3. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
    Patti F.
    Neurodegener Dis Manag; 2019 Apr; 9(2s):3-7. PubMed ID: 30657027
    [Abstract] [Full Text] [Related]

  • 4. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG, Henze T, Essner U, Trompke C, Vila Silván C.
    Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P, Trojano M.
    Eur Neurol; 2016 Dec; 76(5-6):216-226. PubMed ID: 27732980
    [Abstract] [Full Text] [Related]

  • 8. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M, Vila C, Jonas A, Witte K, Álvarez-Ossorio L.
    Eur Neurol; 2016 Dec; 75(5-6):236-43. PubMed ID: 27160412
    [Abstract] [Full Text] [Related]

  • 9. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
    Celius EG, Vila C.
    Brain Behav; 2018 May; 8(5):e00962. PubMed ID: 29761015
    [Abstract] [Full Text] [Related]

  • 10. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
    Fernández O.
    Eur Neurol; 2014 May; 72 Suppl 1():9-11. PubMed ID: 25278117
    [Abstract] [Full Text] [Related]

  • 11. Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing.
    Montero-Escribano P, Vila Silván C.
    Expert Rev Med Devices; 2019 Sep; 16(9):835-840. PubMed ID: 31393179
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
    Contin M, Mancinelli L, Perrone A, Sabattini L, Mohamed S, Scandellari C, Foschi M, Vacchiano V, Lugaresi A, Riva R.
    Clin Neuropharmacol; 2018 Sep; 41(5):171-176. PubMed ID: 30024443
    [Abstract] [Full Text] [Related]

  • 15. Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.
    Di Marzo V, Centonze D.
    CNS Neurosci Ther; 2015 Mar; 21(3):215-21. PubMed ID: 25475413
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
    Syed YY, McKeage K, Scott LJ.
    Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.